Based on the CASI Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for CASI Pharmaceuticals Inc is USD 6.00 over the next 12 months. CASI Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of CASI Pharmaceuticals Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, CASI Pharmaceuticals Inc’s stock price was USD 5.50. CASI Pharmaceuticals Inc’s stock price has changed by +1.85% over the past week, -9.54% over the past month and +19,291.03% over the last year.
No recent analyst target price found for CASI Pharmaceuticals Inc
No recent average analyst rating found for CASI Pharmaceuticals Inc
Company Overview CASI Pharmaceuticals Inc
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc"RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China. Read Less
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditi...Read More
Frequently Asked Questions About CASI Pharmaceuticals Inc (CASI) Stock
Based on ratings from 1 analysts CASI Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on CASI's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CASI is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on CASI's stock to indicate if its overvalued.
The last closing price of CASI's stock was USD 5.50.
The most recent market capitalization for CASI is USD 0.09B.
Based on targets from 1 analysts, the average taret price for CASI is projected at USD 6.00 over the next 12 months.
This means that CASI's stock price may go up by +9.09% over the next 12 months.
We can't find any ETFs which contains CASI Pharmaceuticals Inc's stock.
As per our most recent records CASI Pharmaceuticals Inc has 176 Employees.
CASI Pharmaceuticals Inc's registered address is 1701-1702, China Central Office Tower 1, Beijing, China, 100025.
You can get more information about it from CASI Pharmaceuticals Inc's website at https://www.casipharmaceuticals.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About CASI Pharmaceuticals Inc (CASI) Stock
Based on ratings from 1 analysts CASI Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on CASI's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for CASI is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on CASI's stock to indicate if its overvalued.
The last closing price of CASI's stock was USD 5.50.
The most recent market capitalization for CASI is USD 0.09B.
Based on targets from 1 analysts, the average taret price for CASI is projected at USD 6.00 over the next 12 months.
This means that CASI's stock price may go up by +9.09% over the next 12 months.
We can't find any ETFs which contains CASI Pharmaceuticals Inc's stock.
As per our most recent records CASI Pharmaceuticals Inc has 176 Employees.
CASI Pharmaceuticals Inc's registered address is 1701-1702, China Central Office Tower 1, Beijing, China, 100025.
You can get more information about it from CASI Pharmaceuticals Inc's website at https://www.casipharmaceuticals.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CASI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
